SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2026 · 64 positions · Total reported value $784.53M · Top-10 concentration 54.6% · Updated 2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 64 equity positions with a combined reported value of $784.53M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 54.6% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were KOD ($71.12M), CELC ($63.87M), COGT ($50.42M). By sector, the heaviest allocations are Health Care 95.8%, Financials 3.3%. Versus the prior quarter, allocation shifted toward Financials (+1.4pp), Other (+0.9pp) and away from Health Care (-2.3pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 60% of names.

The largest new positions opened in Q3 2026 were CLDX ($12.01M), KRSP ($8.71M), DARE ($6.80M).

Of the 18 positions fully exited versus the prior quarter, the largest were VCYT ($18.68M), GH ($14.98M), TRVI ($12.65M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • CLDX CELLDEX THERAPEUTICS INC NEW · $12.01M
  • KRSP RAINIER ACQUISITION CORP · $8.71M
  • DARE YARROW BIOSCIENCE INC · $6.80M
  • ARCT ARCTURUS THERAPEUTICS HLDGS · $6.30M
  • KNSA KINIKSA PHARMACEUTICALS INTL · $5.65M
  • EVMN EVOMMUNE INC · $4.91M
  • FTH Faeth Therapeutics Inc · $3.69M
  • RACD RESEARCH ALLIANCE CORP IV · $3.50M

Fully Exited (vs previous quarter)

  • VCYT VERACYTE INC · prev qtr: $18.68M
  • GH GUARDANT HEALTH INC · prev qtr: $14.98M
  • TRVI TREVI THERAPEUTICS INC · prev qtr: $12.65M
  • MANE VERADERMICS INC · prev qtr: $11.68M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $11.28M
  • AVTX AVALO THERAPEUTICS INC · prev qtr: $9.25M
  • WGS GENEDX HOLDINGS CORP · prev qtr: $8.39M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · prev qtr: $5.09M

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 95.8%
Financials 3.3%
Other 0.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 750.17K $71.12M 9.06%
9.06%
Add
2 803.19K $63.87M 8.14%
8.14%
Add
3 1.57M $50.42M 6.43%
6.43%
Add
4 1.15M $46.67M 5.95%
5.95%
Reduce
5 2.09M $45.01M 5.74%
5.74%
Add
6 3.75M $37.01M 4.72%
4.72%
Add
7 152.18K $34.67M 4.42%
4.42%
Reduce
8 348.32K $33.17M 4.23%
4.23%
Add
9 112.79K $25.48M 3.25%
3.25%
Add
10 624.05K $21.08M 2.69%
2.69%
Add
11 236.58K $20.83M 2.65%
2.65%
Reduce
12 247.92K $20.65M 2.63%
2.63%
Reduce
13 1.33M $19.50M 2.49%
2.49%
Add
14 175.70K $17.40M 2.22%
2.22%
Add
15 5.95M $14.82M 1.89%
1.89%
Add
16 151.15K $13.46M 1.72%
1.72%
Add
17 345.95K $13.17M 1.68%
1.68%
Reduce
18 1.21M $12.83M 1.64%
1.64%
Add
19 300.43K $12.17M 1.55%
1.55%
Add
20 370.70K $12.01M 1.53%
1.53%
New
21 3.45M $11.50M 1.47%
1.47%
Add
22 378.35K $10.78M 1.37%
1.37%
Add
23 3.95M $9.40M 1.20%
1.20%
Add
24 6.57M $9.13M 1.16%
1.16%
Add
25 334.06K $9.01M 1.15%
1.15%
Reduce
26 717.36K $8.92M 1.14%
1.14%
Add
27 853.88K $8.71M 1.11%
1.11%
New
28 3.59M $8.54M 1.09%
1.09%
Add
29 1.52M $7.84M 1.00%
1.00%
Add
30 125.08K $7.12M 0.91%
0.91%
Reduce
31 301.92K $6.80M 0.87%
0.87%
New
32 5.36M $6.32M 0.81%
0.81%
Add
33 459.90K $6.30M 0.80%
0.80%
New
34 525.00K $6.26M 0.80%
0.80%
Add
35 19.75K $5.75M 0.73%
0.73%
Reduce
36 75.70K $5.65M 0.72%
0.72%
New
37 121.45K $5.57M 0.71%
0.71%
Reduce
38 760.34K $5.50M 0.70%
0.70%
Add
39 594.03K $4.91M 0.62%
0.62%
New
40 247.42K $4.65M 0.59%
0.59%
Reduce
41 443.11K $4.43M 0.56%
0.56%
Reduce
42 404.73K $4.38M 0.56%
0.56%
Add
43 124.10K $3.69M 0.47%
0.47%
New
44 693.44K $3.64M 0.46%
0.46%
Add
45 301.96K $3.50M 0.45%
0.45%
New
46 216.62K $3.47M 0.44%
0.44%
New
47 2.34M $3.15M 0.40%
0.40%
New
48 47.31K $3.10M 0.40%
0.40%
Reduce
49 2.14M $2.46M 0.31%
0.31%
Hold
50 200.26K $2.20M 0.28%
0.28%
New

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 64 equity positions worth $784.53M in aggregate; its largest disclosed positions were KOD ($71.12M), CELC ($63.87M), COGT ($50.42M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $784.53M of long equity holdings across 64 positions as of 2026-Q3. Top-10 holdings account for 54.6% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →